Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography

BJU International

Volumn 96, Issue 4, 2005, Pages 540-546

  Lawrentschuk, Nathan ^a,b   Poon, Aurora M T ^b   Foo, Serene S ^b   Putra, Lydia G Johns ^a   Murone, Carmel ^b   Davis, Ian D ^a,b   Bolton, Damien M ^a   Scott, Andrew M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

Hypoxia; Pathological neovascularization; Positron emission CT; Radioisotope diagnostic techniques; Renal cell carcinoma

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORINE 18; MISONIDAZOLE; OXYGEN; UNCLASSIFIED DRUG;

ADULT; AGED; APPARATUS; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; NEPHRECTOMY; NON INVASIVE MEASUREMENT; OXYGEN CONSUMPTION; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE OXYGENATION; TUMOR VASCULARIZATION;

ADULT; AGED; ANOXIA; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MISONIDAZOLE; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; OXYGEN; POLAROGRAPHY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 24044503731     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05681.x     Document Type: Article

References (47)

1. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 2003; 510: 285-92
2. Mattern J. Role of angiogenesis in drug resistance. Anticancer Res 2001; 21: 4265-70
3. 18F-fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391-8
4. Fyles AW, Milosevic M, Wong R et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998; 48: 149-56
5. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999; 53: 99-104
6. Gatenby RA, Kessler HB, Rosenblum JS et al. Oxygen distribution in squamouscell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14: 831-8
7. Nordsmark M, Hoyer M, Keller J, Nielsen OS, Jensen OM, Overgaard J. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1996; 35: 701-8
8. Lewis JS, Welch MJ. PET imaging of hypoxia. Q J Nucl Med 2001; 45: 183-8
9. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48
10. Tannock I, Guttman P. Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer 1981; 43: 245-8
11. Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990; 50:3339-44
12. Bonn D. Why do hypoxic cells behave badly? Lancet Oncol 2000; 1: 202
13. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981; 43: 546-50
14. Rasey JS, Grunbaum Z, Magee S et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987; 111: 292-304
15. Yeh SH, Liu RS, Wu LC et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996; 23: 1378-83
16. Rischin D, Peters L, Hicks R et al. Phase I trial of concurrent tirapazamine, cisplatin and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 535-42
17. 18F-fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417-28
18. 18F-fluoromisonidazole. Neurology 1998; 51: 1617-21
19. Tochon-Danguy HJ, Sachinidis JI, Chan F et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002; 29: 191-7
20. 18F-fluorodeoxyglucose (FDG) positron emission tomography. J Nucl Med 2001; 42: 678
21. West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M. Tumor vascularity, a histological measure of angiogenesis and hypoxia. Cancer Res 2001; 61: 2907-10
22. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001; 31: 321-9
23. Sharma RA, Harris AL, Dalgleish AG, Steward WP, O'Byrne KJ. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol 2001; 2: 726-32
24. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-49
25. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28: 36-41
26. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15
27. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Meth Enzymol 2004; 381: 335-54
28. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. Acta Oncol 1994; 33: 383-9
29. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 2004; 6: 291-305
30. Davies P, Brink F. Microelectrodes for measuring local oxygen tensions in animal tissue. Rev Scient Instr 1942; 13: 524
31. Hockel M, Knoop C, Schlenger K et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26: 45-50
32. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31-9
33. Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors. Correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res 1993; 136: 422-34
34. Olive PL, Banath JP, Aquino-Parsons C. Measuring hypoxia in solid tumours - is there a gold standard? Acta Oncol 2001; 40: 917-23
35. Webster L. Drugs used in chemotherapy of protozoal infections. In Taylor P ed. The Pharmacological Basis of Therapeutics. New York: Pergamon Press, 1990: 1002-4
36. Edwards D. Nitromidazole drugs-action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993; 31: 9-20
37. 18F-fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199-212
38. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990; 122: 301-8
39. Graham MM, Peterson LM, Link JM et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 1997; 38: 1631-6
40. Zanzonico P, O'Donoghue J, Chapman JD et al. Iodine-124-labeled iodoazomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004; 31: 117-28
41. Gronroos T, Eskola O, Lehtio K et al. Pharmacokinetics of [18F]FETNIM. a potential marker for PET. J Nucl Med 2001; 42: 1397-404
42. 2O and [18F]fluoroerythronitroimidazole PET. J Nucl Med 2001; 42: 1643-52
43. 18F-FDG PET imaging in soft tissue sarcomas, correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003; 30: 695-704
44. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22: 265-80
45. Zhuang H, Duarte PS, Pourdehnad M, Li P, Alavi A. Standardized uptake value as an unreliable index of renal disease on fluorodeoxyglucose PET imaging. Clin Nucl Med 2000; 25: 358-60
46. Ramdave S, Thomas GW, Berlangieri SU et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825-30
47. Bentzen L, Keiding S, Nordsmark M et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003; 67: 339-44